Preotact endocrine/metabolic data

Data from an investigator-initiated trial in 18 patients with hypoparathyroidism showed that 100 µg NPSP558 given once every other day significantly reduced supplemental calcium requirements by 36% from baseline to 48 months (p<0.01). Additionally, 3 subjects were able to stop all supplemental calcitriol requirements. NPSP558 also significantly reduced phosphorous levels by 0.4 mg/dL and increased bone mineral density (BMD) at the lumbar spine by 6% from baseline to 48 months (p<0.0001 for both). The study was conducted by researchers at Columbia University. Data were presented at the American Society for Bone and Mineral Research meeting in San Diego. ...